The Medicines Company (NASDAQ:MDCO) Files An 8-K Other Events
Item 8.01. Other Events.
The Medicines Company has updated its disclosure regarding its risk factors. The revised risk factor disclosure is filed herewith as Exhibit99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Risk Factors
ExhibitIndex
|
Exhibit Number |
Description |
|
99.1 |
Risk Factors |
MEDICINES CO /DE Exhibit
EX-99.1 2 a18-41461_2ex99d1.htm EX-99.1 Exhibit 99.1 RISK FACTORS Risks Related to Development,…
To view the full exhibit click here
About The Medicines Company (NASDAQ:MDCO)
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company’s products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.
